105438-45-7 Usage
Pyrazole-based amine derivative
It is a chemical compound derived from pyrazole, which is a five-membered heterocyclic aromatic ring system containing two nitrogen atoms.
3-fluorophenyl group
A phenyl ring (a six-membered carbon ring with alternating single and double bonds) with a fluorine atom attached to the third carbon atom.
Methyl group
A carbon atom bonded to three hydrogen atoms, attached to the pyrazole ring.
Pharmaceutical research and development
This compound is commonly used in the field of pharmaceuticals for the development of new drugs and potential therapeutic agents.
Application-dependent properties
The specific properties and potential uses of 2-(3-fluoro-phenyl)-5-methyl-2H-pyrazol-3-ylamine may vary depending on its application in laboratory or industrial processes.
Check Digit Verification of cas no
The CAS Registry Mumber 105438-45-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,5,4,3 and 8 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 105438-45:
(8*1)+(7*0)+(6*5)+(5*4)+(4*3)+(3*8)+(2*4)+(1*5)=107
107 % 10 = 7
So 105438-45-7 is a valid CAS Registry Number.
105438-45-7Relevant articles and documents
Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists
Patnaik, Samarjit,Basu, Dipanwita,Southall, Noel,Dehdashti, Seameen,Wan, Kanny K.,Zheng, Wei,Ferrer, Marc,Taylor, Mercedes,Engel, Daniel A.,Marugan, Juan Jose
, p. 1113 - 1119 (2019)
Nonstructural protein 1 (NS1) plays a crucial function in the replication, spread, and pathogenesis of influenza virus by inhibiting the host innate immune response. Here we report the discovery and optimization of novel pyrazolopyridine NS1 antagonists that can potently inhibit influenza A/PR/8/34 replication in MDCK cells, rescue MDCK cells from cytopathic effects of seasonal influenza A strains, reverse NS1-dependent inhibition of IFN-β gene expression, and suppress the slow growth phenotype in NS1-expressing yeast. These pyrazolopyridines will enable researchers to investigate NS1 function during infection and how antagonists can be utilized in the next generation of treatments for influenza infection.
